Details of the Drug

General Information of Drug (ID: DM6DK9A)

Drug Name
PVX-410
Indication
Disease Entry ICD 11 Status REF
Multiple myeloma 2A83 Phase 2 [1]
Triple negative breast cancer 2C60-2C65 Phase 2 [2]
Solid tumour/cancer 2A00-2F9Z Phase 1 [3]
Cross-matching ID
TTD ID
D06DUS
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
SLAM family member 7 SLAMF7 (CS1) TT7ILZ1 SLAF7_HUMAN Modulator [4]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

ICD Disease Classification 02 Neoplasm
Disease Class ICD-11: 2C82 Prostate cancer
The Studied Tissue Bone marrow
The Studied Disease Multiple myeloma [ICD-11:2C82]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
SLAM family member 7 SLAMF7 (CS1) DTT SLAMF7 9.74E-01 0.13 0.31
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT04634747) A Single-Arm, Open-Label, Multi-Center Phase II Study to Evaluate the Combination of PVX-410 + Pembrolizumab + Chemotherapy for Frontline Therapy of Metastatic, PD-L1+ Triple-Negative Breast Cancer (TNBC) in HLA-A2-Positive Patients. U.S. National Institutes of Health.
3 ClinicalTrials.gov (NCT01718899) Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma. U.S. National Institutes of Health.
4 Market watch: Upcoming catalysts in Q2 2015. Nat Rev Drug Discov. 2015 Apr;14(4):228.